While SMAD4 mutations are known to influence disease progression in some contexts, their lack of association with survival in our cohort may reflect the multifactorial nature of pancreatic cancer prognosis and the influence of co-occurring molecular or clinical features. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.